Cytoprotective Cell Storage Composition Without Cryopreservation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cryopreservation technologies for stem/progenitor cells face challenges such as low cryopreservation efficiency, cryoprotectant toxicity, and cell damage from freezing-thawing cycles, which compromise cell viability and function, especially during short-term storage and transportation.

Innovation Solution

A cytoprotective composition comprising quercetin, taurine hydrochloride, and mildronate, combined with a stabilizing or organ preservation solution, is used to maintain stem/progenitor cells at 4°C to 25°C for up to four weeks without cryoprotectants, preserving cell viability and proliferation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cryopreservation protocol with organic solvent CPAs (DMSO, glycerol) is used, then cell cryopreservation efficiency is improved, but CPA toxicity causes serious side effects and compromises cell viability

Engineering Contradiction:

Improvecryopreservation efficiencyVSAvoidCPA toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and eliminates the toxic organic solvent CPAs (DMSO, glycerol) from the cryopreservation protocol, replacing them with non-toxic alternatives such as sugars (trehalose, sucrose) and amino acids (taurine, glycine) that provide cryoprotection without the harmful side effects associated with conventional CPAs

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the chemical composition parameters of the cryopreservation medium by substituting organic solvents with different chemical classes (carbohydrates, amino acids), and adjusts concentration levels and freezing rates to achieve effective cryopreservation without toxicity

Inventive Principle:

Principle #35Parameter changes

2Reliability

If stepwise freezing with conventional CPAs is used, then cell protection from cryoinjuries is improved, but cell viability and function are compromised after thawing

Engineering Contradiction:

Improvecell protection from cryoinjuriesVSAvoidpost-thaw cell viability

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent converts the harmful freezing-thawing process into a beneficial one by using non-toxic CPAs that protect cells during freezing while allowing full functional recovery after thawing, turning the previously harmful procedure into a safe storage method that maintains cell viability and function

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Duration of action of stationary object

If deep freezing and thawing is performed for long-term storage, then cell storage duration is extended, but cell damage from ice injury and solution injury increases

Engineering Contradiction:

Improvecell storage durationVSAvoidice injury and solution injury

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent applies prior cushioning by pre-treating cells with non-toxic CPAs before freezing, which protects cells from ice crystal formation and solution concentration effects during the freezing-thawing cycles, enabling long-term storage without significant cell damage

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

4Reliability

If conventional cryopreservation protocol is used for transportation, then cell preservation during transport is improved, but transportation cost and risk increase due to expensive equipment and thawing requirements

Engineering Contradiction:

Improvecell preservation during transportVSAvoidtransportation equipment and protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses simple, inexpensive non-toxic CPA formulations (sugars, amino acids) that can be easily implemented in standard transportation containers without requiring expensive cryogenic equipment, making cell transportation more accessible and cost-effective

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS12471592B2Cytoprotective compositions for short-term cells storage and transportation without cryopreservation and deep freezing

Publication Date: 2025.11.18 REELABS INC

AI summary

A short-term storage of stem/progenitor cells in regenerative medicine without cryopreservation and cryoprotector. The protective composition of the invention improves the quality and increases the efficiency of cell therapy by keeping stem/progenitor cells free of ultra-low temperatures (liquid nitrogen) and cryoprotectants during the period of their biosafety testing and transportation to a patient's bed.